Introduction
Global gene expression studies in kidney transplant biopsies have revealed the molecular landscapes of antibody-mediated rejection (ABMR) and T cell-mediated rejection (TCMR) (1, 2) . Both ABMR and TCMR manifest strong expression of IFNG-inducible transcripts (3, 4) , suggesting a shared program for triggering IFNG production by activated NK cells in ABMR and activated T cells in TCMR. When biopsies with ABMR are compared to all other biopsies including TCMR, transcripts representing NK cells and endothelial cell activation are highly associated with ABMR (5, 6) . When TCMR is compared to all other biopsies including ABMR, transcripts representing T cells and myeloid antigen presenting cells stand out (7, 8) . Evidence supporting the triggering of NK cell CD16a-an activating Fc receptor that binds the Fc portions of IgG antibodies-was previously demonstrated in human ABMR (9) , and it is well-established that TCR/CD3 activation is the central antigen recognition event in TCMR.
NK cells and CD8 T cells share expression of multiple effector molecules, activating receptors, and key signaling cascades downstream of their respective receptors. Both NK cells and CD8 T cells express similar levels of cytotoxic molecules, transcription factors regulating cytotoxic and effector potential, and activating and inhibitory NK-type receptors not expressed in CD4 T cells (10) . NK cell CD16a signaling parallels that of TCR triggering in T cells. Both receptors signal through CD3f, which recruits protein tyrosine kinases Syk and Zap70 to ITAMs encoded in its cytoplasmic domain (11) . Phosphorylation of Syk and Zap70 by Src-family kinases (e.g. Lck) (12) engages nearly identical downstream processes in CD16a and TCR signaling, including calciumdependent activation of calcineurin A (13), calcium-independent activation of the SOS/RAS/MEK/ERK axis (14) , and triggering of pathways that lead to actin rearrangement and degranulation (15) (16) (17) (18) , and mobilization of transcription factors NFATc, NFATp, and AP-1 required for increased expression of effector genes such as IFNG (19) (20) (21) (22) .
We previously identified transcripts increased in CD16a-triggered NK cells that provided evidence for CD16a triggering in ABMR (23) . However, it remains unknown how activation-inducible transcripts in NK cells and T cells relate to one another, how these transcripts present in transplant biopsies, and whether any transcript depicting effector lymphocyte activation has diagnostic potential in differentiating between ABMR and TCMR. In the present study, we hypothesized that CD16a triggering in NK cells and TCR/CD3 triggering in T cells represent highly similar effector mechanisms that differ mainly in their modes of antigen recognition, and that these parallel mechanisms should produce common molecular changes in ABMR and in TCMR. We employed new algorithms to identify proteins and transcripts that are simultaneously increased following CD16a-activation of NK cells and TCR/CD3-activation of CD8 T cells and examined their expression in biopsies histologically diagnosed as ABMR or TCMR.
Materials and Methods

Patient population and biopsy collection
As previously described (8), a set of 703 kidney transplant biopsies collected from 579 patients at six kidney transplant centers was histologically classified as per the Banff 2013 report (1) . Patient demographics and clinical details for this set have been published (5, 24) . Biopsies used in this study were restricted to the 534 samples classified as acute kidney injury, ABMR, glomerulonephritis, interstitial fibrosis and tubular atrophy, no major histologic abnormalities (NOMOA), "other," or TCMR. Biopsy collection for this study was approved by the institutional review boards of participating centers. Some biopsies were collected as part of the INTERCOM study (ClinicalTrials.gov NCT01299168).
Transcript expression in biopsies
RNA extraction from biopsies, subsequent labeling, and hybridization to HG-U133 Plus 2.0 GeneChip human gene expression arrays (Affymetrix, Santa Clara, CA) was performed as previously described (24) . CEL files were generated with Affymetrix GeneChip Command Console Software version 4.0. Platforms used in analysis include GeneSpring GX 13.0 (Agilent Technologies, Santa Clara, CA), Microsoft Office Excel (Redmond, WA), and "R" software.
Transcript expression in cultured cells
We used a Ficoll-Paque (GE Healthcare Life Sciences, Baie-D'Urf e, Quebec, Canada) density gradient to isolate peripheral blood mononuclear cells (PBMCs) from the blood of healthy volunteers. Cells were purified using EasySep (Stem Cell Technologies, Vancouver, BC, Canada) negative selection kits, and purity was assessed by flow cytometry. Cells were cultured as specified below.
NK cells: Cells were purified from PBMCs using an EasySep Human NK Cell Enrichment Kit. Data were obtained from three separate cultures of NK cells from three different donors. Purity of CD45+/CD3À/CD56+ cells as a percent of viable cells was 83-96%. NK cells were stimulated with anti-CD16a LEAF antibodies (BioLegend, San Diego, CA) or left unstimulated for 4 h as previously described (23) . IFNG and TNF ELISAs were performed on cell-free supernatants to confirm activation. Cells were lysed in TRIzol Reagent (Life Technologies Inc., Burlington, ON, Canada). Total RNA was collected and analyzed on Affymetrix PrimeView GeneChip human gene expression arrays according to manufacturerrecommended procedures. Gene expression data were averaged across the three cultures. 
CD8 T cells:
Analysis of shared T cell and NK cell transcripts in cell cultures and biopsies
Gene expression data were pre-processed using robust multi-array averaging. We calculated z-scores of probe set fold changes in stimulated versus unstimulated NK cells and CD8 T cells. We eliminated transcripts with >500 expression in no major histologic abnormalities (NOMOA) and nephrectomies, <200 expression in stimulated NK cells or CD8 T cells, and increased >2x in IFNG-stimulated versus unstimulated monocytes. Fold change z-scores for T cells and NK cells were summed and the top 30 transcripts with the highest sum were selected, representing the most highly increased transcripts in both cells. These 30 transcripts are termed "shared activation transcripts" in this manuscript.
To identify non-inducible shared transcripts, we identified transcripts with <500 expression in NOMOA, nephrectomies, and all cells in the primary human cell panel. We selected transcripts with ≥1000 expression in both CD3-stimulated T cells and CD16a-stimulated NK cells. Transcripts increased ≥2x in stimulated versus unstimulated T cells or NK cells were eliminated.
Biopsy data were obtained using HG-U133 chips, but shared activation transcripts were identified using PrimeView arrays, which use different naming conventions to assign probe set IDs to transcripts. To permit comparison between these two platforms, HG-U133 probe set IDs representing shared transcripts' gene symbols were selected on the basis of sequence consensus with PrimeView probe sets, probe set selectivity, and signal intensity.
Results
Expression of shared CD16a and TCR/CD3-inducible molecules in activated NK cells and T cells
We compared changes in soluble mediator and gene expression following in vitro stimulation of primary human NK cells and CD8 T cells via CD16a and TCR/ CD3, respectively. These in vitro studies defined the shared responses that we could later query in kidney transplant biopsies.
We quantified supernatant concentrations of 30 soluble mediators in CD16a-stimulated NK cell and TCR/CD3-stimulated CD8 T cell cultures by a protein array. Supernatants were assayed at 2, 4, 8, and 24 h ( Figure 1 ). IFNG, TNF, CCL3, CCL4, and CSF2 were produced by both cell types, while the other 25 soluble mediators showed limited production (<100 pg/mL) or were not produced by either cell type. These results underscore striking similarity between CD16a-stimulated NK cells and CD3/TCR-stimulated T cells in terms of their patterns of soluble mediator production.
We defined the overlap in gene expression changes in activated NK cells and CD8 T cells after 4 h of stimulation. Pilot experiments revealed that small numbers of contaminating monocytes introduced IFNG-inducible transcripts (>2x increased in IFNG-stimulated vs. unstimulated monocyte cultures) in T and NK cell cultures, so those transcripts were excluded. We examined the 30 most highly increased shared activation transcripts (Table 1) . In preparation for assessments in kidney transplant biopsies, we excluded transcripts with high expression (>500) in nephrectomies and relatively normal transplant biopsies because high background expression would overshadow signals from T cells and NK cells in biopsies. The top 30 most highly increased transcripts in both cell types (by fold change vs. unstimulated cells) included effector cytokines (IFNG, CSF2), chemokines (CCL3, CCL4, XCL1), and membrane proteins such as TNFRSF9 (CD137/4-1BB), CRTAM, and CD160 that affect NK cell and CD8 T cell effector functions (26) (27) (28) (29) (30) (31) .
Taken together, these data imply the existence of a highly conserved program of activation by human NK cells and CD8 T cells that leads to similar transcript expression and production and release of the same limited number of effector cytokines and chemokines.
Expression of shared activation transcripts in kidney transplant biopsies Of the top 30 shared activation transcripts, those that are increased in activated T cells and NK cells with limited expression in other cell types would most clearly reflect shared activation effects in biopsies with ABMR and TCMR. We examined expression of the top 30 shared activation transcripts in a panel of primary human cell types and excluded transcripts with high expression (>500) in any one cell type or mild expression (>100) in all cell types (Table S1 ). The ten transcripts that remained after filtering were considered selective for activated T cells and NK cells: IFNG, XCL1, TNFRSF9, ZBED2, CSF2, RGS16, CD160, SEMA7A, GFI1, and TNFSF14 (LIGHT).
We studied the T cell/NK cell-selective shared activation transcripts in biopsies with histologic ABMR, TCMR, and non-rejection (Table 2) . Mixed rejection cases were omitted. Biopsies classified as borderline, BK virus, and transplant glomerulopathy were omitted from the control groups because they have considerable T cell involvement that may obscure shared activation transcripts from our analyses of rejection (32) (33) (34) (35) . Thus we defined two non-rejection classes of biopsies. The "abnormal nonrejection" class consisted of tissue injury without extensive T cell involvement: histologically classified glomerulonephritis (GN, N = 81), interstitial fibrosis and tubular atrophy (IFTA, N = 72), and biopsies classified as "other" (N = 24). The "normal non-rejection" class included relatively pristine biopsies with NOMOA (N = 116) and acute kidney injury (N = 64). Several shared activation transcripts were slightly higher in abnormal non-rejection than normal non-rejection, reflecting inflammation in the abnormal non-rejection biopsies.
We examined transcripts' associations with ABMR and TCMR versus normal and abnormal non-rejection combined ( Figure 3) . Collectively, the NK cell/T cell-selective shared activation transcripts were significantly increased in both ABMR (mean fold change = 1.2, p = 2.11 9 10
À6
) and TCMR (mean fold change = 1.6, p = 8.54 9 10 À13 ). Individually, IFNG, XCL1, TNFRSF9, and CD160 were most strongly increased in ABMR and TCMR (p < 5 9 10
) whereas the remaining six transcripts were not as strongly associated with rejection, possibly because their expression is subject to additional regulation not identified in this study.
Patterns of increased expression among NK cell/T cellselective shared activation transcripts in vitro were conserved in vivo. CD160 was expressed 11.3-fold more highly in stimulated NK cells versus stimulated T cells and was more strongly associated with histologic ABMR than TCMR. IFNG showed modestly higher expression in stimulated T cells compared to stimulated NK cells and was more strongly associated with histologic TCMR (perhaps because of the higher number of infiltrating lymphocytes). ZBED2 was preferentially associated with TCMR and not ABMR reflective of low ZBED2 expression by NK cells but high expression by T cells. Given that IFNG, XCL1, CD160, and TNFRSF9 are selective for stimulated T cells and NK cells, their association with both histologic ABMR and TCMR supports the concept of shared effector mechanisms of CD16a-activated NK cells in ABMR and TCR/CD3-activated T cells in TCMR.
Expression of non-activation-induced T cell and NK cell transcripts in kidney transplant biopsies Other transcripts constitutively expressed but not regulated by CD16a or TCR/CD3 stimulation should also be shared between TCMR and ABMR (36) because of the increased localization of T cells or NK cells in rejection compared to non-rejection biopsies. We identified transcripts that are highly expressed but not activationinduced in NK cells and CD8 T cells (expression ≥ 1000 and FC < 2x in stimulated vs. unstimulated cells), and studied their expression in kidney transplant biopsies. We selected transcripts with low expression (<500) in all cells in the primary human cell panel and in nephrectomies and NOMOA biopsies. Fourteen unique transcripts met our criteria (Table 3) , including cytolytic molecules (GZMA, PRF1), intracellular signaling molecules (ITK, STAT4), and membrane proteins (CD2, CD8A, CD96, TNFRSF25, IL2RB, KLRC4-KLRK1). All transcripts were strongly associated with both types of histologic rejection. The one exception, ANKRD36, may be explained by its tendency to decrease from its already modest expression following activation. Taken together, these studies illustrate that in addition to the shared T cell and NK cell activation features observed in ABMR and TCMR, features that are highly expressed in T cells and NK cells but not activation induced are also demonstrated in biopsies with ABMR and TCMR.
Discussion
This study examined the hypothesis that CD16a-activated NK cells in ABMR and CD3/TCR-activated T cells in TCMR are highly similar, and that these similarities must impose common features on ABMR and TCMR. Identical shared transcripts defined in vitro were examined in biopsies histologically diagnosed as ABMR and TCMR. Of the 372 transcripts increased in CD16a activated NK cells, 53% (N = 199) were also increased in TCR/CD3-activated CD8 T cells. Transcripts for effector cytokines, chemokines, and other molecules related to effector cell function were common to activation of both T and NK cells. Of the most highly increased shared activation transcripts, CD160, IFNG, XCL1, and TNFRSF9 (4-1BB) showed selective expression in activated NK and T cells (they were not expressed in other cell types in a primary human cell panel) and strong associations with histologically classified ABMR and TCMR. Certain non-inducible transcripts in NK cells and T cells were also strongly associated with histologic ABMR and TCMR including shared T cell/NK cell-selective markers, intracellular signaling proteins, and cytotoxicity mediators. We conclude that overlapping CD16a/TCR-inducible effector functions and non-inducible features of NK cells and T cells are evident in ABMR and TCMR despite differences in antigen recognition systems and cellular localization between these different rejection mechanisms.
The shared chemokines, cytokines, and cytotoxic mediators identified in this study suggest that activated effector T cells and NK cells employ similar mechanisms in mediating rejection. Many of the differences between ABMR and TCMR probably arise because of differences in location of the cognate event: NK cells in the microcirculation (25) engaging donor endothelium, and effector T cells in the interstitium engaging antigen-presenting cells. Note that both types of effector cell may be using mechanisms that are not reflected in activation-induced transcript changes, such as cytotoxic enzyme release from granules.
Our studies highlight many shared elements of CD16a-activated NK cell and TCR/CD3-activated T cells that are manifest in ABMR and TCMR, respectively, and have the potential to drive rejection pathogenesis. CD16a and TCR/CD3 signaling activates cytotoxic degranulation (15) (16) (17) (18) in NK cells and CD8 T cells, respectively, and may damage the graft directly. Chemokines CCL3 and CCL4 increase the availability of proinflammatory cytokines in rejection by recruiting myeloid cells to sites of inflammation (37), while XCL1 recruits additional T cells and NK cells (38) . IFNG produced by activated T and NK cells increases antigen availability in rejection by enhancing HLA expression on endothelial cells and antigen presenting cells (39, 40) in addition to its multiple synergies with TNF (41) (42) (43) and CSF2 (44) CSF2 is often considered a key T H 17 effector cytokine (45, 46 ), yet our data show that activated NK cells and CD8 T cells also produce CSF2 as part of their very limited set of early effector cytokines. Paradoxically, however, CSF2 expression was the same in biopsies with and without histologic rejection, suggesting additional sources of CSF2. CCL4 and CCL3 identified in our study also dominate the list of secreted proteins following phytohemagglutinin stimulation of CD16+ NK cells (47) . Likewise, the same set of CD16a-inducible effector cytokines (IFNG, TNF, CSF2) are observed in response to cytokine-mediated stimulation of NK cells (48) . Thus, our studies highlight a stereotyped effector response common to NK cell CD16a and T cell CD3 activation in ABMR and TCMR and likely reflect a standardized response regardless of the type of stimulus.
These studies highlight molecules that have not previously been studied in ABMR and TCMR such as CD160. CD160 may influence IFNG production by NK cells in ABMR (30) . CD160 triggers cytotoxicity in response to HLA-C (49) and stimulates cytokine secretion by NK cells upon binding class Ia and Ib HLA (29) . Interestingly, a soluble form of CD160 that inhibits cell-mediated cytotoxicity is cleaved from the surface of activated NK cells in the presence of IL-15 (50) . IL-15 is highly expressed in rejecting kidney transplants (51) , suggesting that CD160 may in fact attenuate NK cell cytotoxicity in ABMR. As well as being expressed on a subset of CD8 T cells described as NK-like (52), CD160 is expressed on a subset of exhausted CD8 T cells in chronic viral infections and enhances T cell activation in binding to Herpes Virus Entry Mediator (53) . Thus CD160 may provide clues not only to potential effector functions but also to events that regulate effector function in ABMR and TCMR.
CD160 and IFNG had reciprocal patterns of association with ABMR and TCMR that make them attractive candidates for reporting NK cell and T cell activation, respectively. CD160 was the only shared activation transcript that was more strongly associated with ABMR than TCMR, perhaps because its expression is biased towards stimulated NK cells. Although it is demonstrated in our studies that both T and NK cells produce IFNG, the stronger association of IFNG with TCMR than ABMR may reflect the smaller number of NK cells in ABMR than T cells in TCMR. As proof of concept that it could be used to report effector cell activation, IFNG shows an inverse relationship with the degree of calcineurin inhibition on NK cell activation (54, 55) . However, we propose that CD160 would be more effective at reporting NK cell activation in ABMR because it is more selective for NK cells and easier to detect in ABMR than IFNG. Strong association with TCMR makes IFNG a better candidate for reporting T cell activation in TCMR. Reporting disease activity would be useful in monitoring the effect of immunosuppression on effector cell activation, although further studies will be required to determine whether clinical application of these transcripts is feasible.
Highly similar effector responses by NK cells and T cells offer insights into mechanism of action of immunosuppressive drugs and present opportunities for novel targets. Activation of both cell types should be calcineurin dependent (54, 56) , and calcineurin inhibitors likely help control both NK cell and effector T cell activation, albeit at sub-saturation levels that only partially inhibit calcineurin (57) . Better control might be achieved by 110 ABMR biopsies and 64 TCMR biopsies were used. Abnormal Non-Rejection (NR)-177 biopsies histologically classified as "GN," "IFTA," and "Other." Normal Non-Rejection (NR)-180 biopsies histologically classified as "NOMOA" and "AKI." GN, glomerulonephritis; IFTA, interstitial fibrosis and tubular atrophy; NOMOA, no major histologic abnormalities; AKI, acute kidney injury. 1 Transcripts were excluded if they had >500 expression in any one cell type on the extended cell panel or >100 expression in all cells in the extended cell panel.
American Journal of Transplantation 2018; 18: 63-73pushing the dose, but this is limited by the toxicity of calcineurin inhibitors. CD16a or its activation-induced molecules could be considered potential targets for ABMR therapies, with monitoring of activation molecules such as IFNG, CD160, or XCL1 to measure effects of therapy. Perhaps agents such as anti-CD2, anti-thymocyte globulin and alemtuzumab that deplete both T cells and NK cells (58) should be studied as treatments for ABMR as well as TCMR.
This study does not alter diagnostic algorithms or transcript lists derived in previous work from our group. The shared activation transcripts do not distinguish ABMR (6) from TCMR (8) . Likewise, activation-induced transcripts are rarely used in diagnostic classifiers that assign ABMR and TCMR scores (5,7), and are absent from the 23 previously identified DSA-associated transcripts in patients with clinical indications (25) . Our current results demonstrate that shared transcripts induced following effector lymphocyte activation should not be used for the diagnosis of ABMR or TCMR.
This study used microarrays to find the relevant transcripts in vivo from the list of those mapped in vitro in cell panels. A limitation of this approach is that when transcripts are shared between NK cell and T cells, the proportion of their expression derived from either cell type cannot be determined. However, it is unlikely that T cells primarily drive shared transcripts' expression in ABMR as some of the most statistically significant T cell markers in TCMR (8) were absent from ABMR. Conversely, NK cells do not explain shared transcripts' expression in TCMR because top NK cell-selective transcripts (6, 9, 25) were absent from TCMR. Moreover, this study could not address why some transcripts induced in vitro in stimulated NK cells and T cells were not In all three panels biopsies with rejection were being compared against 357 normal and abnormal non-rejection biopsies histologically classified as acute kidney injury, glomerulonephritis, interstitial fibrosis, and tubular atrophy, no major abnormalities, and "other." p-values were calculated using a Bayesian (moderated) t-test.
increased in ABMR or TCMR. For example, GFI1 was not strongly associated with ABMR or TCMR, possibly because GFI1 can auto-repress its expression (59) and may be only transiently induced by stimuli (60 
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